New mRNA Flu Vaccine Approved: What It Means for Older Adults and Future Vaccinations

The FDA's recent approval of Moderna's mFLUSIVA marks a significant breakthrough in influenza vaccination, particularly for adults aged 50 and older. This mRNA flu shot represents the first of its kind, capitalizing on technology that had gained momentum during the COVID pandemic, and it heralds a new chapter in our approach to flu prevention—especially pertinent given the annual toll of flu-related deaths among older Americans.

Approved on August 5, mFLUSIVA has been designed to address longstanding issues associated with traditional flu vaccines. These conventional vaccines, which have been in use for decades, depend on predicting which flu strains will be prevalent months in advance, often leading to mismatches and less effective immunizations. As Dr. Anna Durbin from Johns Hopkins University points out, evolving vaccine technology has been crucial, and this mRNA vaccine could help expedite our responses to changing viral strains considerably.

Evaluating Safety and Efficacy

The FDA’s advisory committee unanimously concluded that the benefits of mFLUSIVA outweigh any potential risks for older adults. Clinical trials have shown that the vaccine is approximately 26.6% more effective than traditional options at preventing laboratory-confirmed influenza, particularly in those aged 65 and older. It also elicited a stronger immune response, with rates of severe side effects remaining rare. Overall, the positive data led to expedited approval, allowing high-risk groups to receive the vaccine sooner.

In terms of its safety profile, the vaccine has been tested in around 70,000 participants during clinical trials. Real-world effectiveness will notably begin to emerge during the 2026–27 flu season as it reaches populations typically excluded from clinical studies, such as organ transplant recipients or individuals on immunosuppressive treatments. However, existing experiences with mRNA vaccines from COVID provide a positive context for mFLUSIVA.

Comparison with Traditional Vaccines

Traditionally, flu vaccines are either inactivated (grown in eggs) or recombinant, which can take months to prepare. While recombinant vaccines are somewhat quicker, mRNA technology stands out for its ability to respond rapidly to new strains, delivering a genetic blueprint to our cells that instructs them to generate a piece of the virus. This allows for quicker updates and adaptations, critical for addressing fluctuating flu patterns.

Durbin underscores the advantages of mRNA in terms of speed and flexibility. With this new approach, producing a vaccine can become a matter of weeks instead of months, which means adjustments based on real-time strain monitoring can lead to superior matches for flu seasons.

Availability and Market Dynamics

As older adults prepare for the upcoming flu season, mFLUSIVA will be available as an option, though its market penetration and initial demand remain uncharted territories. While FDA approval often leads to health insurance coverage, geography may impede local availability in various pharmacies. It's not yet determined how many doses Moderna will produce or the potential cost of the vaccine, presenting variability in access.

If the price is competitive, mFLUSIVA may become a standard ask alongside traditional vaccines; however, a higher price point could make it more of a niche option. Durbin envisions a scenario where patients might be asked to choose between the mRNA vaccine or the conventional one, contingent on supply dynamics and individual preferences.

Moreover, acceptance of this new vaccine may be affected by widespread vaccine skepticism, particularly surrounding mRNA technology. Moderna may consider a cautious rollout strategy, gathering data on uptake and effectiveness compared to traditional vaccines before fully committing to broader distribution.

Future of Traditional Flu Shots

For the current flu season, traditional vaccines will remain available to older populations. It may be several years before mRNA options extend to younger groups, as each demographic requires its own clinical trials. The real test for mFLUSIVA will rely on documented performance in the general population and whether it can significantly outpace traditional flu vaccines in terms of effectiveness and safety.

The landscape of flu vaccinations could change dramatically based on these findings. Historically, the CDC’s Advisory Committee on Immunization Practices evaluates and recommends vaccines based on efficacy; should mFLUSIVA prove consistently superior with no safety issues, it might emerge as the preferred option in future seasons. Durbin cites the rise of Shingrix as a case study in vaccine evolution, noting that unlike Shingrix, which faced little resistance, mRNA’s reception might play a pivotal role in its adoption.

The upcoming flu season will undoubtedly be telling. Will mFLUSIVA distinguish itself as a notable advancement in vaccine technology? Assessing uptake and efficacy will be crucial in determining whether this represents a meaningful shift in flu protection strategies.

Source: Johns Hopkins University

The post What you should know about the new mRNA flu vaccine appeared first on Futurity.